Literature DB >> 33271878

Modeling Non-Alcoholic Fatty Liver Disease (NAFLD) Using "Good-Fit" Genome-Editing Tools.

Uijin Kim1, Nahyun Kim1, Ha Youn Shin1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD), which affects both adults and children, is the most common liver disorder worldwide. NAFLD is characterized by excess fat accumulation in the liver in the absence of significant alcohol use. NAFLD is strongly associated with obesity, insulin resistance, metabolic syndrome, as well as specific genetic polymorphisms. Severe NAFLD cases can further progress to cirrhosis, hepatocellular carcinoma (HCC), or cardiovascular complications. Here, we describe the pathophysiological features and critical genetic variants associated with NAFLD. Recent advances in genome-engineering technology have provided a new opportunity to generate in vitro and in vivo models that reflect the genetic abnormalities of NAFLD. We review the currently developed NAFLD models generated using clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) genome editing. We further discuss unique features of CRISPR/Cas9 and Cas9 variants, including base editors and prime editor, that are useful for replicating genetic features specific to NAFLD. We also compare advantages and limitations of currently available methods for delivering genome-editing tools necessary for optimal genome editing. This review should provide helpful guidance for selecting "good fit" genome-editing tools and appropriate gene-delivery methods for the successful development of NAFLD models and clinical therapeutics.

Entities:  

Keywords:  CRISPR/Cas9; NAFLD; base editor; genome engineering; prime editor

Mesh:

Year:  2020        PMID: 33271878      PMCID: PMC7760008          DOI: 10.3390/cells9122572

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  91 in total

1.  Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease.

Authors:  P-F Chang; Y-C Lin; K Liu; S-J Yeh; Y-H Ni
Journal:  Int J Obes (Lond)       Date:  2015-04-03       Impact factor: 5.095

2.  Baculovirus-based genome editing in primary cells.

Authors:  Maysam Mansouri; Zahra Ehsaei; Verdon Taylor; Philipp Berger
Journal:  Plasmid       Date:  2017-01-22       Impact factor: 3.466

3.  Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.

Authors:  Dominik Paquet; Dylan Kwart; Antonia Chen; Andrew Sproul; Samson Jacob; Shaun Teo; Kimberly Moore Olsen; Andrew Gregg; Scott Noggle; Marc Tessier-Lavigne
Journal:  Nature       Date:  2016-04-27       Impact factor: 49.962

4.  Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

Authors:  Qiurong Ding; Alanna Strong; Kevin M Patel; Sze-Ling Ng; Bridget S Gosis; Stephanie N Regan; Chad A Cowan; Daniel J Rader; Kiran Musunuru
Journal:  Circ Res       Date:  2014-06-10       Impact factor: 17.367

5.  Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.

Authors:  Elizabeth K Speliotes; Laura M Yerges-Armstrong; Jun Wu; Ruben Hernaez; Lauren J Kim; Cameron D Palmer; Vilmundur Gudnason; Gudny Eiriksdottir; Melissa E Garcia; Lenore J Launer; Michael A Nalls; Jeanne M Clark; Braxton D Mitchell; Alan R Shuldiner; Johannah L Butler; Marta Tomas; Udo Hoffmann; Shih-Jen Hwang; Joseph M Massaro; Christopher J O'Donnell; Dushyant V Sahani; Veikko Salomaa; Eric E Schadt; Stephen M Schwartz; David S Siscovick; Benjamin F Voight; J Jeffrey Carr; Mary F Feitosa; Tamara B Harris; Caroline S Fox; Albert V Smith; W H Linda Kao; Joel N Hirschhorn; Ingrid B Borecki
Journal:  PLoS Genet       Date:  2011-03-10       Impact factor: 5.917

6.  TraFo-CRISPR: Enhanced Genome Engineering by Transient Foamy Virus Vector-Mediated Delivery of CRISPR/Cas9 Components.

Authors:  Fabian Lindel; Carolin R Dodt; Niklas Weidner; Monique Noll; Fabian Bergemann; Rayk Behrendt; Sarah Fischer; Josephine Dietrich; Marc Cartellieri; Martin V Hamann; Dirk Lindemann
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-17       Impact factor: 8.886

7.  MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics.

Authors:  Elena Vila-Navarro; Elena Fernandez-Castañer; Maria Rovira-Rigau; Giulia Raimondi; Maria Vila-Casadesus; Juan Jose Lozano; Philippe Soubeyran; Juan Iovanna; Antoni Castells; Cristina Fillat; Meritxell Gironella
Journal:  Oncogenesis       Date:  2020-05-04       Impact factor: 7.485

8.  Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease.

Authors:  Salvatore Petta; Luca Miele; Elisabetta Bugianesi; Calogero Cammà; Chiara Rosso; Stefania Boccia; Daniela Cabibi; Vito Di Marco; Stefania Grimaudo; Antonio Grieco; Rosaria Maria Pipitone; Giulio Marchesini; Antonio Craxì
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

9.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Authors:  Yang-Lin Liu; Helen L Reeves; Alastair D Burt; Dina Tiniakos; Stuart McPherson; Julian B S Leathart; Michael E D Allison; Graeme J Alexander; Anne-Christine Piguet; Rodolphe Anty; Peter Donaldson; Guruprasad P Aithal; Sven Francque; Luc Van Gaal; Karine Clement; Vlad Ratziu; Jean-Francois Dufour; Christopher P Day; Ann K Daly; Quentin M Anstee
Journal:  Nat Commun       Date:  2014-06-30       Impact factor: 14.919

10.  An autoregulatory enhancer controls mammary-specific STAT5 functions.

Authors:  Gil Metser; Ha Youn Shin; Chaochen Wang; Kyung Hyun Yoo; Sumin Oh; Alejandro V Villarino; John J O'Shea; Keunsoo Kang; Lothar Hennighausen
Journal:  Nucleic Acids Res       Date:  2015-10-07       Impact factor: 16.971

View more
  1 in total

1.  Growth hormone ameliorates hepatopulmonary syndrome and nonalcoholic steatohepatitis secondary to hypopituitarism in a child: A case report.

Authors:  Xiao-Yuan Zhang; Ke Yuan; Yan-Lan Fang; Chun-Lin Wang
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.